Add Presentation to Slide Tray Presentation:
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
Conclusions (1 of 3)
- Few clinically important differences are found between first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) in core illness symptoms or response and remission rates in treating schizophrenia or bipolar disorder.
- No class effects for either benefits or adverse effects of antipsychotics can be assumed based on the evidence to date.
- The evidence base about comparative effectiveness and safety is inadequate for informed decisionmaking because of sparse data, imprecise effect estimates, and concerns about study usefulness (high risk of bias, wide variety of outcome measures).
- Abou-Setta AM, Mousavi SS, Spooner C, et al. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness. Comparative Effectiveness Review No. 63 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC054-EF. Available at www.effectivehealthcare.ahrq.gov/antipsychotics-adult.cfm.
Your slide tray is being processed.